This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR hits a 52-week high as optimism builds around KT-621's progress and upcoming data in atopic dermatitis.
SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYNegative Net Change JNJNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
FDA Greenlights Novartis' Gene Replacement Treatment for SMA
by Zacks Equity Research
Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA patient group.
NVSPositive Net Change BAYRYPositive Net Change FOLDNegative Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Down as Rybelsus Misses Goals in 2 Alzheimer's Studies
by Zacks Equity Research
Novo Nordisk stock declines on the failure of two phase III studies evaluating oral Rybelsus for treating early-stage symptomatic AD.
NVONegative Net Change ADMAPositive Net Change EDITPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
by Zacks Equity Research
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
REGNNegative Net Change SNYNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
pharmaceuticals
Biogen Inks Research Deal With Dayra to Boost Immunology Pipeline
by Zacks Equity Research
BIIB's research deal with Dayra targets oral macrocyclic peptides to advance its immunology pipeline and expand next-generation therapies.
BIIBNegative Net Change ADMAPositive Net Change EDITPositive Net Change ARQTNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
AZNNegative Net Change JNJNegative Net Change PFENegative Net Change LLYNegative Net Change
pharmaceuticals
Company News for Nov 25, 2025
by Zacks Equity Research
Companies In The News Are: CVAC, CAAP, NVO, BABA.
NVONegative Net Change BABANegative Net Change CAAPNo Net Change CVACNegative Net Change
airlines biotechnology internet-content pharmaceuticals
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
by Zacks Equity Research
LLY, EPHE, BBC, HELX, XHS and SURI headline last week's top-performing ETFs as healthcare and biotech outperform a weak broader market.
LLYNegative Net Change BBCNegative Net Change XHSPositive Net Change EPHEPositive Net Change HELXNegative Net Change SURIPositive Net Change
pharmaceuticals
Top Stock Reports for Alphabet, Roche & RTX
by Mark Vickery
Alphabet gains momentum as AI-driven growth in Cloud, Search and YouTube fuels rising customer adoption and revenue strength.
RHHBYNegative Net Change MUPositive Net Change AMPPositive Net Change GOOGLPositive Net Change CFFIPositive Net Change CRAWAPositive Net Change RTXPositive Net Change SOLVNegative Net Change
aerospace computers finance industrial-products pharmaceuticals
BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study
by Zacks Equity Research
Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.
JNJNegative Net Change BAYRYPositive Net Change FOLDNegative Net Change CRMDPositive Net Change
biotechnology medical pharmaceuticals
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
by Zacks Equity Research
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
PFENegative Net Change MRKNegative Net Change CRMDPositive Net Change CSTLPositive Net Change
pharmaceuticals
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
by Ahan Chakraborty
Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Lilly Crosses $1 Trillion Market Cap: Here's What Is Driving the Rally
by Sundeep Ganoria
LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
by Sanghamitra Saha
Lilly's $1T valuation and soaring GLP-1 demand spotlight ETFs like IHE, PPH, MEDI, OZEM, MEDX and THNR for investors riding the weight-loss drug boom.
LLYNegative Net Change IHENegative Net Change PPHNegative Net Change MEDINegative Net Change MEDXNegative Net Change THNRNegative Net Change OZEMNegative Net Change
etfs pharmaceuticals
Top Research Reports for JPMorgan Chase, Netflix & AbbVie
by Mark Vickery
JPMorgan's year-to-date gains, NII growth outlook and investment banking pipeline headline today's standout Zacks research picks.
JPMNegative Net Change EQIXPositive Net Change NFLXNegative Net Change ALLPositive Net Change RSGNegative Net Change ABBVNegative Net Change OVBCPositive Net Change
consumer-discretionary finance pharmaceuticals
Healthcare ETFs to Buy as Big Pharma Rapidly Integrates AI
by Aparajita Dutta
LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.
JNJNegative Net Change LLYNegative Net Change NVDANegative Net Change ABBVNegative Net Change XLVNegative Net Change VHTNegative Net Change PLTRPositive Net Change
etfs pharmaceuticals
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNNegative Net Change MRKNegative Net Change ADMAPositive Net Change EDITPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYPositive Net Change FOLDNegative Net Change RNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNNegative Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
by Kinjel Shah
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
AZNNegative Net Change BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
Top Analyst Reports for Visa, Merck & Southern Company
by Mark Vickery
Visa sees solid volume growth and cross-border gains, while Merck and Southern Company navigate competitive and regulatory pressures.
SONegative Net Change VNegative Net Change ETRPositive Net Change MRKNegative Net Change TTWOPositive Net Change CHCIPositive Net Change CMTVNo Net Change GEHCNegative Net Change
business-services construction finance pharmaceuticals utilities
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITPositive Net Change COGTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals